These days, glucose isn’t the only thing that Abbott Labs (NYSE:ABT) is having to monitor. After developing a presence in the world of diabetes care through its MediSense division, Abbott solidified their market position with its acquisition of TheraSense in 2004, resulting in the formation of Abbott Diabetes Care. In an effort to defend its glucose monitoring division from new entrants, Abbott Diabetes Care initiated a costly legal battle with DexCom, Inc. that is still underway.
ShareThis
